Cancer Immunology and Oncolytic Virology: Technologies and Global Markets
Report Highlights
The global cancer immunotherapies market reached $30.8 billion in 2012. This market is expected to grow to nearly $34.3 billion in 2013 and $67.9 billion in 2018 with a compound annual growth rate (CAGR) of 14.7% over the five-year period, 2013 to 2018.
Report Includes
- An overview of the global market for cancer immunotherapies
- Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018.
- Analyses of factors influencing market demand such as clinical guidelines, demographic changes, and market saturation
- Technological discussion including the current state, newly issued patents, and pending applications
- Profiles of leading companies in the industry.
SCOPE OF REPORT
The scope of this study entails the current immunology therapeutics markets for several of the most common cancers. The sectors covered are colony stimulating factors (CSFs), interferon alfa and gamma products, interleukin products and therapeutic monoclonal antibodies, including antibody conjugates, cancer vaccines and other cancer treatment immunology products. Vaccines against HPV and hepatitis B are included; while such vaccines act only indirectly against cancer, they do serve to protect against the disease. Also covered is oncolytic virology, so new that its market tables have been presented separately from the immunotherapy tables. The report also includes discussion of the regulatory environment, current and developing technologies, cancer incidence, market projections and market share, along with latest trends and clinical trials.
ANALYST CREDENTIALS
Valerie Kellogg is an experienced medical device and pharmaceutical professional with international market research experience. She has authored numerous reports on topics ranging from treatment of obesity to ablation devices, from wound care to treatment of chronic migraine. Her strong focus areas include treatment of chronic disease, the latest in surgical devices and analysis of potential acquisitions.